Rheumatology Billing Services: Why Rheumatology Practices Lose Revenue on Their Most Expensive Treatments

By Medtransic Team | March 8, 2026 | 10 min read | Updated: July 3, 2026

Quick Summary: A rheumatology practice that runs an infusion suite is operating a pharmacy, a bank, and a clinic at once: it buys biologics costing thousands of dollars per vial, fronts that cost, and recovers it one claim at a time. When an infusion claim fails, the loss isn't a visit fee — it's the drug. Here's how buy-and-bill, waste modifiers, prior auth, and step therapy actually decide rheumatology margins.

Most specialties lose money on billing errors in units of visit fees. Rheumatology loses it in units of drug vials. An infusion practice purchases infliximab, rituximab, tocilizumab, or abatacept up front — real money out the door — and recovers that cost only when the claim pays. A coding error on an office visit costs the visit. A failed infusion claim costs the visit, the chair time, the nurse, and a drug acquisition cost that can run thousands of dollars. That asymmetry should reorganize how a rheumatology practice thinks about billing: the infusion suite is where the risk concentrates, and everything about its claims deserves procedure-level discipline.

This article walks through the actual mechanics — buy-and-bill economics, infusion claim structure, the waste-modifier rules, and the authorization gauntlet — that separate profitable infusion programs from ones that quietly subsidize their payers. It's the operating knowledge behind Medtransic's rheumatology billing program.

• Per 10 mg Infliximab Billing Unit - Unit-count errors scale with the dose
• 1st hour Complex Infusion Administration - Additional hours and drugs bill their own codes
• JW / JZ Waste Attestation Modifiers - Required on single-dose vials since July 2023
• US-guided Large-Joint Injection - A different code — and payment — than a blind injection

Buy-and-Bill: The Drug Is the Risk

The buy-and-bill model is simple to describe and unforgiving to run: the practice buys the drug, administers it, and bills the payer for the drug plus the administration. Medicare Part B pays physician-administered drugs on a published formula — average sales price plus a fixed add-on percentage — which means the margin on the drug is thin, known in advance, and entirely dependent on flawless claims. There is no pricing cushion to absorb a denial, a units error, or a missed authorization. Commercial payers negotiate their own drug rates, and an increasing number push "white bagging" arrangements — the drug shipped from a specialty pharmacy instead of bought by the practice — which changes the economics of every affected patient and is worth modeling deliberately rather than accepting by default.

The practical consequence: a rheumatology practice should know, per payer, exactly what each biologic reimburses versus what it costs to acquire — and its billing partner should be able to produce that analysis. Practices that don't run this math occasionally discover they've been infusing a particular drug for a particular payer at a loss for years.

Anatomy of an Infusion Claim

A biologic infusion claim is a small machine with several moving parts, each of which can fail independently:

• The drug line: the drug's J-code with the correct number of billing units. These units are drug-specific rather than one-per-vial (infliximab, for example, bills per 10 mg), so a 400 mg dose is 40 units — and a biller who enters 4, or 400, has either donated 90% of the drug or filed a claim that screams for review.
• The administration codes: the first hour of a complex biologic infusion, each additional hour, and any sequential or concurrent drugs — each with its own code, all built on documented start and stop times. No times in the chart, no defensible hours billed.
• Pre-medications: commonly administered before biologics and billable with their own drug and administration codes when documented — a small, steady leak when ignored.
• The diagnosis linkage: the diagnosis coded must match the authorization and the payer's coverage policy for that drug — right drug, right diagnosis, wrong linkage is still a denial.

None of this is exotic — it's just precise, and the cost of imprecision is denominated in drug dollars. An infusion program's claims deserve a pre-submission check that reconciles dose, units, times, and authorization on every single encounter.

JW and JZ: The Waste Modifiers That Stop Payment Cold

Biologics come in single-dose vials, and doses are weight-based — so waste is routine: a 380 mg dose drawn from 400 mg of vials leaves 20 mg discarded. Medicare's rule since July 2023 is strict and binary: every single-dose-vial drug claim must either report the discarded amount on a separate line with the JW modifier, or carry the JZ modifier attesting that no waste occurred. Claims that do neither are rejected, and unit counts that don't reconcile against real vial sizes invite audits. The waste line, properly reported, is also payable — meaning practices that under-document waste are both non-compliant and underpaid, a rare double.

Prior Auth and Step Therapy: The Gate in Front of Everything

Every biologic in the rheumatology arsenal sits behind prior authorization, and increasingly behind step therapy — the payer's requirement that the patient fail cheaper agents before the prescribed one is covered. For billing purposes, the authorization isn't paperwork; it's the condition that makes a four-figure drug claim payable. The failure modes are specific: the authorization expired mid-course and nobody tracked the date; the dose was escalated clinically but the auth still says the old dose; the drug was switched and infused under the previous drug's approval; the patient's plan changed January 1 and the new payer never issued an auth at all. Each one converts a delivered infusion into a full-cost loss, and post-hoc appeals on no-auth denials are the worst-odds fight in billing.

The operational answer is an authorization ledger that lives next to the infusion schedule: every upcoming infusion checked against a current, dose-accurate, drug-accurate authorization before the patient sits down. That check is cheap. The infusion it protects is not. A rheumatology billing partner should run this as core service — Medtransic's prior authorization workflow exists precisely because the drug's cost makes the gate worth staffing.

Beyond the Infusion Suite

The cognitive side of rheumatology bills like other chronic-disease specialties, with the same opportunities internists chronically miss: multi-condition medication management supporting a higher-complexity office visit under the current rules, time-based leveling for data-heavy visits, and Medicare's longitudinal-care add-on for panels that are, by nature, forever. The procedure side has one recurring trap worth naming: joint injections. Blind injections (coded by joint size) and ultrasound-guided injections (with required image documentation) are different codes with different payments — and the corticosteroid or viscosupplement injected bills separately from the injection procedure itself. Practices whose superbill offers only "joint injection" leave both distinctions, and the associated payment, uncollected.

What to Ask a Rheumatology Billing Partner

Infusion billing competence is auditable in one conversation:

1. Walk me through your pre-submission check on an infusion claim: dose-to-units reconciliation, start/stop times, JW/JZ handling, and authorization match. Which of those do you verify on every claim?
2. What's your process when nursing documentation is missing stop times or waste amounts — query, or bill what's there?
3. Can you produce a per-payer margin analysis: what each biologic reimburses versus acquisition cost?
4. Who tracks authorization expiration dates and dose changes against the infusion schedule — you or my staff?
5. How do you handle the January payer-change wave for patients mid-course on a biologic?
6. On joint injections, does your coding distinguish ultrasound-guided from blind — and is the injected drug on every claim?

A rheumatology practice's billing quality is measured in drug dollars protected. The rules in this article — units, times, waste, authorization — are all checkable against your own recent claims, which is exactly what Medtransic's rheumatology billing program does on engagement, with denial management and prior authorization support built in. The same infusion-billing discipline drives high-dollar drug reimbursement in our oncology billing guide. Request a billing review and we'll audit your infusion claims line by line.

Sources & References

• CMS — Medicare Part B drug payment (ASP pricing files)
• CMS — JW/JZ modifier requirements for discarded drug amounts
• AMA — drug administration and joint injection code families
• American College of Rheumatology — practice management and coding resources